chrisvoncsefalvay/vaers-outcomes huggingface dataset:
body aches; chills; feeling weak; This is a spontaneous report from a contactable consumer(patient).  The 62-year-old female patient received bnt162b2 (COVID-19 VACCINE), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as single dose for covid-19 immunization.  Medical history was none. The patient's concomitant medications were not reported.  After having first COVID-19 vaccine, she experienced body aches, chills and feeling weak. Outcome of events was unknown.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
11/18/05 Mom states arm hot/swollen, red to elbow, having headaches.  Advised Tylenol, warm compresses.  11/21/05 Mom states no headaches, swelling almost gone, down in size to 5 inches.
This is a spontaneous report from a contactable pharmacist.  A 32-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as 1st dose, single for COVID-19 immunization. Medical history and concomitant medications were not reported.  The reporter stated that the patient had first dose of PFIZER-BIONTECH COVID-19 VACCINE and then the patient got a case of the shingles on an unknown date. The reporter wanted to know if this will affect the patient's second dose. Outcome of the event was unknown.   Information on the lot/batch number has been requested.
Pt. c/o pain/itching/ swelling at injection site beginning 2 days after vaccines given. Exam today (5/4/2012) arm still tender and 2" area at injection site is swollen.
Raised, swollen area around injection site (right arm), pain and numb feeling in arm.
face paralysis; This is a spontaneous report from a contactable consumer reporting on behalf of her husband.  A 43 year old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Lot number unknown), via an unspecified route of administration on 06Feb2021 (at an unknown age) as a single dose for COVID-19 vaccination. Medical history was not reported. Concomitant medications were not reported. The reporter stated her husband received the first dose of the COVID 19 vaccine on 06Feb2021 and was scheduled for the second dose on 19Feb2021 He woke up today (18Feb) with face paralysis. He went to the doctor, got a CT scan and other studies, and everything is normal. The reported stated that the doctor said it was probably the vaccine. Doctor prescribed medication and told him not to get the second dose. Lab data included CT scan and "other studies" on 18Feb2021 which were normal. The clinical outcomes of facial paralysis was unknown.
Swelling of arm; Large rectangular lump (2" x 3"); bright red and very tender; fever; general body aches; mild upset stomach and nausea. Lasted 4 days. Localized redness, lump and tenderness hadve lessened, but still remain.
This spontaneous report was received from a physician, via company representative, referring to a female patient who was currently 21 years old. The pertinent medical history, current conditions and concomitant therapies were not reported. In February 1995, the patient was vaccinated with RECOMBIVAX HB lot # 612921/1152A (strength, doses, expiration date and administration route were not reported). On an unknown date, the patient experienced thrombocytopenia after receiving the RECOMBIVAX HB and was hospitalized at an unspecified hospital. The outcome of thrombocytopenia was unknown. The causality between the event and the RECOMBIVAX HB was not reported. Upon internal review thrombocytopenia was considered to be medically significant event. No product quality complaint (PQC) was involved. Additional information has been requested.
Bright red and warm, sore rash surrounded by red spots all around, making it a 6 x 6 area tender.
Chronic fatigue, headaches, pneumonia, abdominal cramping, bloating, constipation most started within a month of receiving vaccine.
Pt was behind on immunizations, was given what was due and behind on, after approx. 1/2 hr pt was still in wait room and started having SOB and wheezing. Was given O2 by mask, 25 mg BENADRYL and Albuterol TX. Pt was able to breath normally and was transferred to ER by ambulance for further eval.
There is a large red spot around the injection site. It itches, is warm, and slightly hard.
It was reported that a 48 year old female received Fluzone SV '99-'00 on 10/14/99. The same day, she experienced a "local reaction of redness, warmth and swelling". No further information is available at this time.
This spontaneous report was received from a licensed practical nurse and refers to an unspecified number patient of unknown age and sex who on an unknown date, were vaccinated with improperly stored doses of GARDASIL 9. No adverse effects were reported. The outcome of incorrect product storage was unknown. This is one of several reports received from the same source. Additional information has been requested.
48 hours post vax, the pt developed a half dollar sized red firm area at injection site, slightly warm to the touch and a dime sized red, firm area left inguinal area.
pt recv vax & devel an inj site rxn characterized by redness & induration;
Initial literature report received on 01 Nov 2010: This patient participated in a prospective cohort study to evaluate T cell responses as correlates of protection against influenza following vaccination in older adults. The patients were vaccinated with Influenza virus vaccine 2007/2008 (seasonal influenza vaccine, manufacturer unknown, batch number: unknown) during the fall of 2007. The influenza surveillance was initiated at two study sites at the start of the influenza season in Jan 2008. The mean age of the study subjects was 74 years (range 60-92). Patients started reporting influenza-like illness (ILI) symptoms. When reported symptoms met the ILI criteria and were within 5 days of onset, a nasal swab for detection of influenza virus was obtained during a home visit or a clinic visit. A laboratory diagnosis of influenza illness was confirmed by the detection of influenza virus in a polymerase chain reaction (PCR) assay of the nasal swabs or a 4-fold or greater rise in the antibody titer after the illness. Subjects that met both  clinical and at least one of the laboratory criteria were identified as laboratory-confirmed influenza (LCL). This patient had an antibody titer value of 40, 40, 40, and 160 after 0 weeks, 4 weeks, 10 weeks and 20 weeks of vaccination respectively. The patient had 4-fold increase in titer value and tested positive for seroconversion of A/H3N2 strain. Therefore this patient was considered as an LCI case of Influenza A/H3N2. The outcome was not reported.
Arm stiff with pain on raising up. Basically she says is that it is aching and painful.
Within 24-48 hours I had a reaction comparable to Covid symptoms. I was in and out of it, had fever for a couple of days, and within 7 days I was over these Covid-like symptoms and my interstitial cystitis became extremely flared and I was just in a lot of pain, had discomfort, and for a month I wasn't able to get out of bed or leave the house without medication. I started seeing a urologist and they prescribed me new medication and we also did multiple instillations and they inserted medications into my bladder and that lasted 3 months until I was able to be normal. I am normal now but have flare ups once a month and it used to not be like that. I am going to see another specialist at the hospital on 02/02 because people in Hickory have tried but can't get it under control. I've had a overall decrease in health and feeling fatigued and sick often.
Patient walked to chair in waiting room after the vaccine and sat down.  She began to feel  dizzy and slid out of the chair to floor. She did not hit her head but felt dizzy and foggy for a few minutes. Given water to sip on. Put onto cot. 911 called, assessed by paramedics and signed refusal to go to hospital.  Also c/o headache. BP=186/103 and pulse=76. Pulse ox=100%. Rested  on cot for a little while. Felt better and sent home with father.
fever is 102.9; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever is 102.9) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever is 102.9). At the time of the report, PYREXIA (fever is 102.9) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 102.9 (High) fever is 102.9.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported.  No treatment medication was reported.
vertigo; nausea; This spontaneous case was reported by an other and describes the occurrence of VERTIGO (vertigo) and NAUSEA (nausea) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VERTIGO (vertigo) and NAUSEA (nausea). At the time of the report, VERTIGO (vertigo) had not resolved and NAUSEA (nausea) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not provided.  Treatment information was not provided.   This case was linked to MOD-2021-099052 (Patient Link).
child presented with a hive, red approximately one inch in diameter with a white area inside of the red area, underneath the bandaide where the varicella vaccine was given, left arm subq
pt preg, LMP 11/17/98; preg confirmed by ultrasound & BHCG; pt had miscarriage @ 9wk gestational age;pt had D&C;
After the 2nd injection I experienced flulike symptoms for 36-48 hours. I checked my blood pressure on the second day and the monitor said I had an irregular heartbeat- my bp is usually 120 over 70- it was slightly elevated my pulse was 85- so I called my doctor- I was experiencing shortness of breath and didn't feel right- very tired- my doctor- listened to my heart with his stethescope and immediately ordered an EKG- the EKG was normal- he then ordered a Echocardiogram- that came out normal- but I still had an irregular heartbeat- it lasted for 3 weeks- I am feeling better now- and the problem has not happened again- I think it had something to do with the second maderna shot-
Body ache; Chest pain when breathing; Inflammation below underarm; Vaccination site inflammation; Vaccination site hardness; Fever; Chills; Axillary pain; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Body ache), CHEST PAIN (Chest pain when breathing), LYMPHADENOPATHY (Inflammation below underarm), VACCINATION SITE INFLAMMATION (Vaccination site inflammation) and VACCINATION SITE INDURATION (Vaccination site hardness) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Diabetes.    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Jan-2021, the patient experienced MYALGIA (Body ache), CHEST PAIN (Chest pain when breathing), LYMPHADENOPATHY (Inflammation below underarm), VACCINATION SITE INFLAMMATION (Vaccination site inflammation), VACCINATION SITE INDURATION (Vaccination site hardness), PYREXIA (Fever), CHILLS (Chills) and AXILLARY PAIN (Axillary pain). On 11-Jan-2021, MYALGIA (Body ache), CHEST PAIN (Chest pain when breathing), LYMPHADENOPATHY (Inflammation below underarm), VACCINATION SITE INFLAMMATION (Vaccination site inflammation), VACCINATION SITE INDURATION (Vaccination site hardness), PYREXIA (Fever), CHILLS (Chills) and AXILLARY PAIN (Axillary pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. No treatment details was provided .; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Vaccines were administered in the period following a temperature excursion but prior to the stability assessment information; Vaccines were administered in the period following a temperature excursion but prior to the stability assessment information; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccines were administered in the period following a temperature excursion but prior to the stability assessment information), POOR QUALITY PRODUCT ADMINISTERED (Vaccines were administered in the period following a temperature excursion but prior to the stability assessment information) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. ASKU) for COVID-19 prophylaxis.   No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccines were administered in the period following a temperature excursion but prior to the stability assessment information), POOR QUALITY PRODUCT ADMINISTERED (Vaccines were administered in the period following a temperature excursion but prior to the stability assessment information) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccines were administered in the period following a temperature excursion but prior to the stability assessment information), POOR QUALITY PRODUCT ADMINISTERED (Vaccines were administered in the period following a temperature excursion but prior to the stability assessment information) and NO ADVERSE EVENT (No adverse event) outcome was unknown.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccines were administered in the period following a temperature excursion but prior to the stability assessment information) and POOR QUALITY PRODUCT ADMINISTERED (Vaccines were administered in the period following a temperature excursion but prior to the stability assessment information).    No concomitant medications were reported.  No treatment information was provided.
See attached hospital report. Auto immune response; brain damage; still recovering 6 months later. May take one year or more.
June start of myasthenia graves affecting eyes. currently treated with pyridostigmine 60mg aid, experiencing double vision and light sensitivity
This case was reported by a healthcare professional and described the occurrence of bruise at the injection site in a female subject of unspecified age who was vaccinated with TWINRIX (GlaxoSmithKline). Co-suspect vaccinations included unspecified vaccine(s); manufacture(s) unspecified; unknown on an unspecified date. On an unspecified date, the subject received an unspecified dose TWINRIX (unknown). At an unspecified time after vaccination with TWINRIX, the subject experienced a bruise at the injection site. The reporting nurse inquired if TWINRIX could be administered in the gluteal area, since the subject experienced a bruise after her last TWINRIX vaccine. In addition, the nurse stated that the patient received other unspecified vaccines on the TWINRIX vaccination, so she was unspecified. No further information was provided. Follow-up information was received on 26 August via a nurse, who stated that she did consider this to be an adverse event. It was unclear if the subject received the TWINRIX vaccine in her thigh or deltoid.
Information has been received from a physician concerning a 17 year old female who on 04-AUG-2009 was vaccinated with the first dose of GARDASIL (lot number unknown) in her right arm. Concomitant therapy included MENACTRA and VAQTA (manufacturer unknown). On 05-AUG-2009 the patient experienced hives and rashes on various parts of body including her inner thighs. The hives and rashes were not at the injection site. The patient was not recovered. Unspecified medical attention was sought. Additional information has been requested.
Information has been received from a physician concerning his daughter a female with no pertinent medical history who was vaccinated with GARDASIL vaccine (yeast). Subsequently the patient experienced ringing in her ears after vaccination. On an unspecified date, the patient recovered from ringing in her ears. The reporter felt that ringing in the patient's ears was not related to therapy with GARDASIL vaccine (yeast). The MRI was performed. The patient sought medical attention. No further information is available.
Tingly feeling and numbness throughout my body since the vaccine shot. No other symptom but it is constant. Visited the ER on Monday June 7th - testing only revealed a bulging disc in the neck. Doctors do not believe it is related to the vaccine
sick; Initial information was received on 21-Nov-2020 regarding an unsolicited valid non serious case from a non-health care professional (patient) via social media.  This case involves a patient of unknown demographics who reported of being sick (illness) post vaccination with INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, family history and concomitant medication were not reported.    On an unknown date, the patient received INFLUENZA VACCINE (produced by unknown manufacturer) (batch number and expiry date were not reported) at an unknown dose, via unknown route a an unknown administration site for prophylactic vaccination.  On an unknown date, (latency unknown) the patient reported of being sick (illness). The patient had experienced the same sickness both the times the patient had received the vaccine.  No laboratory data was reported.  It was not reported if the patient had received any corrective treatment.  At the time of reporting, outcome of the event was unknown.  There will be no information available regarding batch number in this number. .
Left arm with hard lump 50 x 50 mm, 30 x 30 mm bruised area in center, with 60 x 25 mm area of redness, warm to touch, painful.
PAIN AT INJECTION SITE; SEVERE MUSCLE ACHES; Chills; Headache; Fatigue; FEVER; This spontaneous report received from a pharmacist concerned a African American, Not Hispanic/Latino patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 06-MAR-2021 for prophylactic vaccination.  .Batch number was not reported has been requested. No concomitant medications were reported. On MAR-2021, the subject experienced fever. On 06-MAR-2021, the subject experienced pain at injection site. On 06-MAR-2021, the subject experienced severe muscle aches. On 06-MAR-2021, the subject experienced chills. On 06-MAR-2021, the subject experienced headache. On 06-MAR-2021, the subject experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from severe muscle aches, chills, headache, and fatigue on 07-MAR-2021, was recovering from pain at injection site, and the outcome of fever was not reported. This report was non-serious. This case, from the same reporter is linked.
The day after receiving the vaccine, had a sore left arm where the first shot had been given. (The second shot was given higher up on the same arm.) Arm started turning red and was tender and warm to the touch. Started feeling achy everywhere. Took ibuprofen and Tylenol, and felt better, but arm continued to have red mark. Had slight fever that night, and felt much better two days after the vaccine, but red spot on arm continued to grow in size and was tneder. By the third day after the vaccine, I felt fine except for the sore arm. It is not as sore, but is now itchy....The red mark has grown to be a welt about 7 by 4 inches in size. It feels like it should be all better in the next couple of days.
I tested positive for COVID-19 in December 2022.  I had coughing, head congestion, runny nose but no fever.  The symptoms lasted about 9 days.  I consulted the doctor on December 28th and was prescribed an antiviral.  As of today, the only long-term symptom I have is fatigue after simple chores.
Hand numbness then loss of grip strength then progressed to leg weakness gradual onset. EMG positive for Guillain Barre Syndrome and Hospitalized for IVIG on 06/16/2010. Resolution of symptoms at office visit on 06/23/2010.
Left deltoid pain , swelling, tenderness severe enough to interfere with use of left arm for a week at time of report.
arm soreness at the injection site; redness at the injection site; mild headache; This is a spontaneous report received from contactable reporter(s) (Physician). The reporter is the patient.  A 70-year-old female patient received BNT162b2 (BNT162B2), on 22Dec2020 at 12:00 as dose 1, single (Lot number: EJ1685), in left deltoid for covid-19 immunisation. The patient's relevant medical history included: "Hyperlipidemia" (ongoing), notes: Hyperlipidemia, Did not have symptoms just had bloodwork that diagnosed this.; "Uveitis", start date: 2020 (ongoing), notes: Uveitis, Onset date about 2 years ago. Uveitis relapse on day 4 of this last reaction, around 19Apr2022.; "Lupus" (ongoing), notes: Lupus Onset date: Probably had all her life, but started having complications about 5 years ago; "It asks are you allergic to gelatin and she is if it is bovine" (unspecified if ongoing), notes: It asks are you allergic to gelatin and she is if it is bovine. Concomitant medication(s) included: HYDROXYCHLOROQUINE taken for lupus-like syndrome, start date: 2017; ZETIA taken for hyperlipidaemia; PREDNISOLONE taken for uveitis, start date: 2020. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 23Dec2020 at 12:00, outcome "recovered" (25Dec2020), described as "arm soreness at the injection site"; HEADACHE (non-serious) with onset 23Dec2020 at 12:00, outcome "recovered" (25Dec2020), described as "mild headache"; VACCINATION SITE ERYTHEMA (non-serious) with onset 23Dec2020 at 12:00, outcome "recovered" (25Dec2020), described as "redness at the injection site". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient mentioned that with the first dose she experienced arm soreness at the injection site, redness at the injection site, and may have had a mild headache; all of which started about 24 hours after first dose was administered. She had recovered completely after about 1.5 days after onset of these events. Prior Vaccinations patient did not received any other vaccinations within four weeks prior to the first administration date of the suspect vaccine.
Fever, headache, vomiting, diarrhea, red, swelling at site, achy all over. Tx: ADVIL, TYLENOL, rest.
Moderate cellulitis and fever within 24 hours with an erythematous, edematous and vesicular rash on left thigh.  Start on oral antibiotics (Clindamycin) and topical antibiotics (Mupirocin).  Advised to also continue Benadryl for the allergic reaction and Hydrocortisone cream if he develops itching around the injection sites.